Newsroom
Sorted by: Latest
-
Altasciences achève l’agrandissement de son laboratoire de recherche et développement à Harleysville, en Pennsylvanie
LAVAL, Québec--(BUSINESS WIRE)--Altasciences a le plaisir d’annoncer l’agrandissement de son laboratoire de R&D sur son site de Harleysville, en Pennsylvanie, dédié aux services de formulation et de fabrication de médicaments, avec l’ajout d’environ 768 pieds carrés d’espaces de laboratoire supplémentaires. Cet agrandissement permet de regrouper les fonctions de développement des formulations et d’analyse au sein d’un même laboratoire. Cette configuration intégrée vise à accélérer la prise...
-
LabPMM®推出全球KMT2A MRD檢測服務,支援Menin抑制劑研發與急性白血病診療
聖地牙哥--(BUSINESS WIRE)--(美國商業資訊)-- Invivoscribe®旗下子公司LabPMM®今日宣布,其全新的KMT2A微小殘留病灶(MRD)檢測服務現已在全球推出。這項高靈敏度的數位PCR服務透過LabPMM的全球實驗室網路向醫療保健提供者、臨床研究人員和生物製藥合作夥伴開放,其中經過CAP/CLIA認證的檢測服務將在美國地區提供。該服務旨在滿足對於急性白血病精準分子監測與日俱增的需求。1,2,3 KMT2A重排(KMT2A r)是急性髓系白血病(AML)和急性淋巴細胞白血病(ALL)中的致癌驅動因素。4這類重排存在於約80%的嬰兒白血病病例以及5-15%的兒童和成人白血病病例中。5攜帶KMT2A重排的白血病通常與化療抗藥、高復發率和較差的臨床預後相關。5 Menin抑制劑的出現正在改變AML和ALL病患的治療格局,特別是對於攜帶KMT2A重排和NPM1突變的病患。6首款獲得FDA核准用於治療攜帶KMT2A易位的復發或難治性急性白血病的Menin抑制劑,確立了這一新興藥物類別的臨床價值。7隨著Menin抑制劑計畫向一線治療和聯合療法研究推進,臨床日益需要高靈...
-
LabPMM®推出全球KMT2A MRD检测服务,助力Menin抑制剂研发与急性白血病诊疗
圣迭戈--(BUSINESS WIRE)--(美国商业资讯)-- Invivoscribe®旗下子公司LabPMM®今日宣布,其全新的KMT2A微小残留病灶(MRD)检测服务现已面向全球推出。这项高灵敏度的数字PCR服务通过LabPMM的全球实验室网络向医疗保健提供者、临床研究人员和生物制药合作伙伴开放,其中经过CAP/CLIA认证的检测服务将在美国地区提供。该服务旨在满足对于急性白血病精准分子监测日益增长的需求。1,2,3 KMT2A重排(KMT2A r)是急性髓系白血病(AML)和急性淋巴细胞白血病(ALL)中的致癌驱动因素。4这类重排存在于约80%的婴儿白血病病例以及5-15%的儿童和成人白血病病例中。5携带KMT2A重排的白血病通常与化疗耐药、高复发率和较差的临床预后相关。5 Menin抑制剂的出现正在改变AML和ALL患者的治疗格局,特别是对于携带KMT2A重排和NPM1突变的患者。6首款获得FDA批准用于治疗携带KMT2A易位的复发或难治性急性白血病的Menin抑制剂,确立了这一新兴药物类别的临床价值。7随着Menin抑制剂项目向一线治疗和联合疗法研究推进,临床日益需要高灵...
-
LabPMM® lanza un servicio global de análisis de MRD para KMT2A con el fin de apoyar el desarrollo de inhibidores de Menin y la atención a la leucemia aguda
SAN DIEGO--(BUSINESS WIRE)--LabPMM®, una filial de Invivoscribe® anunció el día de hoy la disponibilidad a nivel mundial de su nuevo servicio de análisis de enfermedad residual medible (MRD, por sus siglas en inglés) para el gen KMT2A. Este servicio de PCR digital de alta sensibilidad está a disposición de los profesionales sanitarios, los investigadores clínicos y los socios biofarmacéuticos a través de la red global de laboratorios de LabPMM, con pruebas acreditadas por CAP/CLIA disponibles e...
-
Altasciences schließt Erweiterung seines Forschungs- und Entwicklungslabors in Harleysville, Pennsylvania, ab
LAVAL, Québec--(BUSINESS WIRE)--Altasciences freut sich bekannt zu geben, das F&E-Labor an seinem Standort für Dienstleistungen in der Arzneimittelformulierung und -herstellung in Harleysville, Pennsylvania, erweitert und dabei rund 768 Quadratfuß neue Laborfläche geschaffen zu haben. Die Erweiterung führt die Formulierungsentwicklung und analytische Prüfungen in einem einzigen Labor zusammen. Diese integrierte Struktur soll die Entscheidungsfindung beschleunigen, Arbeitsabläufe straffen un...
-
European AI Startups Grab Record 55% of VC Capital as H1 Funding Reaches $23B
AMSTERDAM--(BUSINESS WIRE)--European AI startups raised a record-breaking $23 billion in the first half of 2026, a 130% year-over-year surge that captured 55% of all venture capital in the region, according to the 2026 European AI Economy Report released today by HumanX and Crunchbase. Up from $10 billion in H1 2025, the historic funding total signals that Europe is rapidly asserting itself as a primary engine of global AI innovation. "If the AI story was supposed to be a two-horse race, Europe...
-
xSuite Positioned as the Leader in the SPARK MatrixTM: Accounts Payable Automation (APA), 2026 by QKS Group
AHRENSBURG, Germany--(BUSINESS WIRE)--QKS Group has named xSuite as a technology leader in the SPARK Matrix™: Accounts Payable Automation (APA), Q2 2026. xSuite, with its comprehensive technology for Accounts Payable Automation (APA), has received strong ratings across the parameters of technology excellence and customer impact. The QKS Group SPARK Matrix™ evaluates vendors based on technology excellence and customer impact. It offers an in-depth analysis of global market dynamics, major trends...
-
DoveRunner Strengthens Forensic Watermarking Leadership Ahead of IBC 2026 with Independent Validation and New Sports Customer
SAN JOSE, Calif.--(BUSINESS WIRE)--DoveRunner, a content security company protecting premium video for broadcasters, OTT platforms and content owners worldwide, today announced two milestones for its Forensic Watermarking solution ahead of IBC 2026: independent robustness testing results from Cartesian, a Bounteous Company, and a new customer agreement with Sportradar. Cartesian's testing evaluated whether DoveRunner's forensic watermark remains detectable after the processing, compression and...
-
DXP Enterprises, Inc. Announces Acquisition of Mequipco Ltd.
HOUSTON--(BUSINESS WIRE)--DXP Enterprises, Inc. (NASDAQ: DXPE) today announced that it has completed the acquisition of Mequipco Ltd. (“Mequipco”). Founded in 1974, Mequipco is headquartered in Calgary, Alberta Canada and operates out of three locations servicing Western Canada including British Columbia, Alberta, Saskatchewan, and Manitoba. Mequipco is a leading Canadian manufacturer representative for mechanical equipment used in water and wastewater systems for municipal and industrial appli...
-
CORRECTING and REPLACING Powerlaw Corp. (Nasdaq: PWRL) Announces Share Repurchase Authorization to Purchase up to 10% of Outstanding Common Shares
SAN FRANCISCO--(BUSINESS WIRE)--Please replace the release dated July 21, 2026, with the following corrected version due to multiple revisions. The updated release reads: POWERLAW CORP. (NASDAQ: PWRL) ANNOUNCES SHARE REPURCHASE AUTHORIZATION TO PURCHASE UP TO 10% OF OUTSTANDING COMMON SHARES Powerlaw Corp. (Nasdaq: PWRL), a publicly traded closed-end fund advised by Powerlaw Fund Adviser, LLC, today announced that its Board of Directors has authorized a 12-month share repurchase program. Under...